Centre moves to tighten controls on antibiotic manufacturing, bulk drug trade

The Centre plans to introduce stringent regulations on antibiotic manufacturing and distribution as a strategy to counteract antimicrobial resistance. Newly proposed measures require manufacturers to secure central approval for antimicrobial licenses, coupled with enhanced quality assessments. Wholesalers will also need distinct licenses for bulk drugs, promoting improved monitoring. Stakeholders are encouraged to provide public comments on these draft amendments prior to their finalization.

Sharing Is Caring:

Leave a Comment

Exit mobile version